Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Top Cited Papers
- 1 August 2014
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 384 (9941) , 403-413
- https://doi.org/10.1016/s0140-6736(14)60494-3
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Hepatitis C therapy updateCurrent Opinion in Gastroenterology, 2012
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435Antimicrobial Agents and Chemotherapy, 2010
- In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease InhibitorAntimicrobial Agents and Chemotherapy, 2009
- Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapyGut, 2006
- An Algorithm for the Grading of Activity in Chronic Hepatitis CHepatology, 1996
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- The CES-D ScaleApplied Psychological Measurement, 1977